A5015452702- Cancer Genomics and Diagnostics
- Molecular Biology Techniques and Applications
- Cancer Cells and Metastasis
- Cutaneous Melanoma Detection and Management
- Cancer, Hypoxia, and Metabolism
- Plant Pathogens and Fungal Diseases
- Forest Insect Ecology and Management
- Prostate Cancer Treatment and Research
- Adrenal and Paraganglionic Tumors
- Immunotherapy and Immune Responses
- Genetic factors in colorectal cancer
- Melanoma and MAPK Pathways
- Single-cell and spatial transcriptomics
- Neuroblastoma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Neuroendocrine Tumor Research Advances
- Genetics, Aging, and Longevity in Model Organisms
- HER2/EGFR in Cancer Research
- Glycosylation and Glycoproteins Research
- Thyroid Cancer Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Estrogen and related hormone effects
- Lung Cancer Research Studies
- Cancer Research and Treatments
- bioluminescence and chemiluminescence research
University of Florence
2015-2025
Azienda Ospedaliero-Universitaria Careggi
2023-2025
Tumour Institute of Tuscany
2010
University of Siena
2007
Florence (Netherlands)
1999-2006
International Centre for Genetic Engineering and Biotechnology
1996
Ninewells Hospital
1995
// Francesca De Luca 1, * , Giada Rotunno 2, Salvianti 3, Galardi 1 Marta Pestrin Stefano Gabellini Lisa Simi 3 Irene Mancini Alessandro Maria Vannucchi 2 Mario Pazzagli Angelo Di Leo Pamela Pinzani Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Istituto Toscano Tumori, 59100, Italy Department Experimental and Clinical Medicine, University Florence, 50139, Clinical, Biomedical Sciences, These authors contributed equally to this work Correspondence to: Pinzani, email:...
In cancer patients, circulating cell-free DNA (ccfDNA) can contain tumor-derived (ctDNA), which enables noninvasive diagnosis, real-time monitoring, and treatment susceptibility testing. However, ctDNA fractions are highly variable, challenges downstream applications. Therefore, established preanalytical work flows in combination with cost-efficient reproducible reference materials for ccfDNA analyses crucial analytical validity subsequently clinical decision-making.We describe the efforts...
Context:Cell-free nucleic acids circulating in plasma are considered a promising noninvasive tool for cancer monitoring. BRAFV600E mutation cell-free DNA (cfDNA) could represent an appropriate marker papillary thyroid carcinoma (PTC).
Cell-free DNA in blood (cfDNA) represents a promising biomarker for cancer diagnosis. Total cfDNA concentration showed scarce discriminatory power between patients and controls. A higher specificity diagnosis can be achieved by detecting tumor specific alterations cfDNA, such as integrity, genetic epigenetic modifications. The aim of the present study was to identify sequential multi-marker panel able increase predictive capability cutaneous melanoma comparison with each single marker alone....
Uveal melanoma is one of the most deadly diseases in ophthalmology for which markers able to predict appearance metastasis are needed. The study investigates role circulating tumor cells (CTC) as a prognostic factor this disease. We report detection by Isolation Size Epithelial Tumor (ISET) cohort 31 uveal patients: we identified single CTCs or clusters 17 patients, while control population, subjects with choroidal nevi, showed no CTC peripheral blood. presence did not correlate any clinical...
// Ida Landini 1 , Andrea Lapucci Alessandro Pratesi 2 Lara Massai Cristina Napoli 3 Gabriele Perrone Pamela Pinzani 4 Luigi Messori 2, * Enrico Mini 1, and Stefania Nobili 3, Department of Experimental Clinical Medicine, University Florence, Firenze, Italy Chemistry “Ugo Schiff”, Health Sciences, Biomedical These authors have contributed equally to this work Correspondence to: Mini, email: enrico.mini@unifi.it Nobili, stefania.nobili@unifi.it Messori, luigi.messori@unifi.it...
Cell-free DNA (cfDNA) quantity and quality in plasma has been investigated as a non-invasive biomarker cancer. Previous studies have demonstrated increased cfDNA amount length different types of cancer with respect to healthy controls. The present study aims test the hypothesis that presence longer strands circulating can be considered for tumor thyroid We adopted quantitative real-time PCR (qPCR) approach based on quantification two amplicons (67 180 bp respectively) evaluate integrity...
Within the OMITERC prospective study (OMIcs application from solid to liquid biopsy for a personalised ThERapy of Cancer), we explored prognostic role encompassing cell-free DNA (cfDNA) and circulating tumour cells (CTCs) in KRAS mutated metastatic colorectal cancer (mCRC). We defined workflow including pre-analytical analytical procedures collecting blood before therapy every 3 months until disease progression (PD). CTCs were counted by CellSearch® isolated DEPArray™. NGS sequencing cfDNA...
We describe a PCR-based assay for determining c-erbB-2 oncogene amplification in breast cancer which we use the TaqMan system. Two fluorogenic probes anneal to target between primers and beta-globin genes contain both reporter dye (6-carboxy-fluorescein) quencher (6-carboxy-tetramethyl-rhodamine). During extension phase of PCR cycle, 5'-->3' exonuclease activity Taq polymerase cleaves hybridized probe, resulting an increase fluorescence emission that is quantitative amount product and, under...